What is NDC 80425-0347?

80425-0347 is the product NDC for Betaloan SUIK, Betamethasone sodium phosphate 3 mg/mL; Betamethasone acetate 3 mg/mL injection, suspension, listed with the FDA by Advanced Rx Pharmacy of Tennessee, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Betaloan SUIK (Betamethasone Sodium Phosphate and Betamethasone Acetate).

What is the active ingredient?

Betamethasone sodium phosphate, Betamethasone acetate.

Advanced Rx Pharmacy of Tennessee, LLC, NDC labeler code 80425. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Betaloan SUIK?

1 other product NDC are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Betaloan SUIK NDC 80425-0347 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)80425-0347Labeler and product segments. Claims need a package NDC.

Product NDC at billing width80425-0347Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
80425-0347-1	80425034701	1 VIAL, MULTI-DOSE in 1 CARTON (80425-0347-1) / 5 mL in 1 VIAL, MULTI-DOSEMarketed from Jul 26, 2023

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Betaloan SUIK
Generic name (nonproprietary): betamethasone sodium phosphate and betamethasone acetate
Active ingredients: Betamethasone sodium phosphate — 3 mg/mLBetamethasone acetate — 3 mg/mL
Dosage form: Injection, Suspension
Route: Intra-articular, Intralesional, Intramuscular
Labeler: Advanced Rx Pharmacy of Tennessee, LLCNDC labeler code 80425
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Jul 26, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 80425-0347_2a9c3847-6363-8f9e-e063-6394a90a15c9SPL ID 2a9c3847-6363-8f9e-e063-6394a90a15c9SPL set ID 016a47f2-8524-4178-e063-6294a90ab36eUNII 7BK02SCL3W, TI05AO53L7
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N480425034701 followed by a unit qualifier and the quantity

Package 80425-0347-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 31, 2024.

Indications (excerpt from the label)

INDICATIONS AND USAGE When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hyp…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 80425-0347

What is NDC 80425-0347?: 80425-0347 is the product NDC for Betaloan SUIK, Betamethasone sodium phosphate 3 mg/mL; Betamethasone acetate 3 mg/mL injection, suspension, listed with the FDA by Advanced Rx Pharmacy of Tennessee, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Betaloan SUIK (Betamethasone Sodium Phosphate and Betamethasone Acetate).
What is the active ingredient?: Betamethasone sodium phosphate, Betamethasone acetate.
Who is the labeler?: Advanced Rx Pharmacy of Tennessee, LLC, NDC labeler code 80425. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Betaloan SUIK?: 1 other product NDC are listed under this name. See all Betaloan SUIK NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Betaloan SUIK NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Betaloan SUIKbetamethasone sodium phosphate and betamethasone acetate	Betamethasone sodium phosphate 3 mg/mL; Betamethasone acetate 3 mg/mL	Injection, SuspensionIntra-articular, Intralesional, Intramuscular	Asclemed USA, Inc.	76420-240	76420-0240-01